NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $4.53 +0.10 (+2.26%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About TriSalus Life Sciences Stock (NASDAQ:TLSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$4.33▼$4.6550-Day Range$3.67▼$4.6752-Week Range$3.33▼$10.42Volume38,153 shsAverage Volume38,411 shsMarket Capitalization$138.12 millionP/E RatioN/ADividend YieldN/APrice Target$12.08Consensus RatingBuy Company OverviewTriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.Read More… Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. TriSalus Life Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreTLSI MarketRank™: TriSalus Life Sciences scored higher than 88% of companies evaluated by MarketBeat, and ranked 144th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingTriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTriSalus Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.26% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 5.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.26% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 5.96%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.31 News SentimentTriSalus Life Sciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for TriSalus Life Sciences this week, compared to 1 article on an average week.Search Interest4 people have searched for TLSI on MarketBeat in the last 30 days. MarketBeat Follows3 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have bought 144,780.00% more of their company's stock than they have sold. Specifically, they have bought $72,440.00 in company stock and sold $50.00 in company stock.Percentage Held by Insiders32.80% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSI Stock News HeadlinesHead-To-Head Survey: TriSalus Life Sciences (TLSI) versus Its CompetitorsNovember 19, 2024 | americanbankingnews.comComparing TriSalus Life Sciences (TLSI) & Its CompetitorsNovember 17, 2024 | americanbankingnews.comTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.November 23, 2024 | Weiss Ratings (Ad)TriSalus Life Sciences price target lowered to $11 from $12 at CanaccordNovember 16, 2024 | markets.businessinsider.comTriSalus Life Sciences: Strong Growth and Strategic Partnerships Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comRoth MKM Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)November 15, 2024 | markets.businessinsider.comTriSalus Life Sciences (NASDAQ:TLSI) Upgraded to "Strong-Buy" at Roth CapitalNovember 15, 2024 | americanbankingnews.comTriSalus Life Sciences sees FY25 revenue growth ‘more than 50%’November 15, 2024 | markets.businessinsider.comSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $8.45 at the start of the year. Since then, TLSI shares have decreased by 46.4% and is now trading at $4.53. View the best growth stocks for 2024 here. Who are TriSalus Life Sciences' major shareholders? Top institutional shareholders of TriSalus Life Sciences include Geode Capital Management LLC (0.66%), MSD Partners L.P. (0.13%), Vestcor Inc (0.08%) and Virtu Financial LLC (0.07%). Insiders that own company stock include Mary T Szela, George Kelly Martin and Mats Wahlstrom. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB). Company Calendar Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CUSIPN/A CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Target$12.08 High Stock Price Target$16.00 Low Stock Price Target$10.00 Potential Upside/Downside+166.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,040,000.00 Net Margins-206.24% Pretax Margin-205.69% Return on EquityN/A Return on Assets-236.83% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio2.00 Sales & Book Value Annual Sales$18.51 million Price / Sales7.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-6.76Miscellaneous Outstanding Shares30,490,000Free Float20,490,000Market Cap$138.12 million OptionableNot Optionable Beta0.49 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:TLSI) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.